We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Co-occurrence of second primary malignancy in patients with thyroid cancer.
- Authors
Hsu, C.-H.; Huang, C.-L.; Hsu, Y.-H.; Iqbal, U.; Nguyen, P.-A.; Jian, W.-S.
- Abstract
Background: The discovery of asynchronous or synchronous double or multiple malignancies in patients is not uncommon. The co-occurrence of second primary malignancy (SPM) could be randomly occurring or association with risk factors such as environmental, genetic predisposition and therapy-related.Materials and methods: We retrieved ∼782 million claim records consisting of 10.8 million males and 10.6 million females from Taiwan’s National Health Insurance, which were collected for a period of 3 years (January 2000–December 2002). All the patient records were stratified by gender and ages at a 20-year interval with SPMs and specific groups. Interestingness or Q-value was used to measure strength of the disease–disease associations.Results: A total of 9423 thyroid cancer (female: 7483, male: 1940), 276 184 SPM (female: 141 023, male: 135 161) and 861 co-occurrence cases (female: 583, male: 278) were recorded. The co-occurrence incidence rate of head and neck, breast, digestive system and lung was 1.93%, 1.59%, 1.44% and 1.18%, respectively. Malignancy of salivary glands, laryngx, sarcoma, lymphoid tissue, mouth, central nervous system and lungs found Q-value >10. Malignancies with intermediate Q-values (5.0–9.9) were observed in nasopharynx, kidney and ureter, breast, stomach and skin. Prostate, leukemia, urinary bladder, ovary, colon, liver and uterine cervix cancer have lower Q-values (1.0–4.9).Conclusion: Co-occurrence ratio of thyroid cancer and SPM was high, occurred in all organ systems. We postulated that the aggressive use of modern diagnostic modalities, aggressive radioiodine treatment, pre-existing molecular oncogen mutations, and thyroid hormone for simultaneously supple-mentary and suppressive therapies were responsible.
- Subjects
THYROID cancer patients; DISEASE susceptibility; NATIONAL health insurance; MEDICAL records; THERAPEUTIC use of iodine isotopes; TUMOR suppressor genes; GENETIC mutation
- Publication
QJM: An International Journal of Medicine, 2014, Vol 107, Issue 8, p643
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcu051